<SEC-DOCUMENT>0000950170-25-087068.txt : 20250617
<SEC-HEADER>0000950170-25-087068.hdr.sgml : 20250617
<ACCEPTANCE-DATETIME>20250617080029
ACCESSION NUMBER:		0000950170-25-087068
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20250617
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250617
DATE AS OF CHANGE:		20250617

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ventyx Biosciences, Inc.
		CENTRAL INDEX KEY:			0001851194
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				832996852
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40928
		FILM NUMBER:		251051851

	BUSINESS ADDRESS:	
		STREET 1:		12790 EL CAMINO REAL, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 945-2393

	MAIL ADDRESS:	
		STREET 1:		12790 EL CAMINO REAL, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vtyx-20250617.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-06-16T20:10:15.4623+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:vtyx="http://ventyxbio.com/20250617" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_17ef4d16-81c4-4b61-8ac4-b458e72e019a" name="dei:AmendmentFlag" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f">false</ix:nonNumeric><ix:nonNumeric id="F_1ef6366d-ea1d-44f6-a3f4-b068f20a9b09" name="dei:EntityCentralIndexKey" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f">0001851194</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="vtyx-20250617.xsd"/></ix:references><ix:resources><xbrli:context id="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001851194</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-17</xbrli:startDate><xbrli:endDate>2025-06-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_194c83bc-a4a5-4150-a45a-0583ee835261" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_cea4b8c1-5323-43f6-838d-83ba0c408d4d" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 17, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e60820d7-78b6-4db8-ac6b-546ff0938ca1" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VENTYX BIOSCIENCES, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c5bc63e4-7739-4cc0-a6af-6d7c667fed73" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_37c43592-87e3-4dd6-9f6d-7f4b071293bd" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-40928</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_96c50338-f833-490a-bf4a-0d6db6676e02" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">83-2996852</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_83b36abe-9d02-4733-b294-dff60f0e6fe7" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12790 El Camino Real</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7ad14e67-c52c-4a6e-b1d0-24b3104f318b" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 200</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_649e0921-571a-499c-acc4-cdbaf7f0688b" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_d4a365cc-aba8-4f90-8a40-b87db098a681" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ce51e629-d4a0-4f67-8388-eb7c37d63a55" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92130</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_bd51347b-9974-47bd-8dd4-ecabde4aedde" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">760</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_71808cd5-234d-47e0-878a-7a9b27842df7" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">407-6511</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14fc0fae-6762-4bde-9186-fb564babafbf" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5db35dc3-6102-493f-bd88-9c5c9060494c" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef5ede58-39ad-4fc0-aab1-1869d1469e51" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_495bbfe1-9ace-4cbd-96e4-e97f9df68732" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5ca31d10-838c-493e-befd-bdfda48383d4" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9a09f27e-17f4-4eac-a023-f351928ab1ed" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VTYX</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f41c9fd4-b972-4d38-a80b-3573ff26f468" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_fd409922-f515-4f3a-a938-2f419cdde066" contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 17, 2025, Ventyx Biosciences, Inc. (the &#8220;Company&#8221;), issued a press release announcing top-line data from its Phase 2a safety and biomarker trial evaluating its CNS-penetrant NLRP3 inhibitor, VTX3232, in patients with early-stage Parkinson&#8217;s disease. The press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8.01 Other Events.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 17, 2025, the Company announced top-line data from its Phase 2a safety and biomarker trial evaluating its CNS-penetrant NLRP3 inhibitor, VTX3232, in patients with early-stage Parkinson&#8217;s disease. The single-center, open-label Phase 2a trial evaluated a 40mg oral daily dose of VTX3232 in ten patients with early-stage, idiopathic Parkinson&#8217;s disease over a 28-day treatment period.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following was observed from the top-line data in the Phase 2a trial:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All adverse events were mild or moderate in severity and assessed as unrelated to study treatment. No serious adverse events were reported.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Steady state concentrations of VTX3232 in cerebral spinal fluid (&#8220;CSF&#8221;) and plasma exceeded the IC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for NLRP3 inhibition by &#8805;3-fold for a full 24-hours post-dose, demonstrating a pharmacokinetic profile.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A high correlation between plasma and CSF exposures across the Company&#8217;s Phase 1 trial and this Phase 2a trial of VTX3232 was observed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reductions in levels of downstream biomarkers of NLRP3-inhibition  in plasma and CSF were observed with VTX3232. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment was associated with improvement in both motor and non-motor symptoms of Parkinson&#8217;s disease, as measured by MDS-UPDRS. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other exploratory markers including sTREM2, GFAP, S100B, NfL, A&#946;40 and A&#946;42, were either unchanged and/or fluctuated within normal levels and no acute changes in exploratory PET imaging were observed, consistent with a 28-day study.</span></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The observations disclosed above are historical, based on preliminary data and summarized by the Company, and thus reflective of the Company&#8217;s interpretation of the data from the Phase 2a study. The above should therefore be interpreted with appropriate caution and should not be interpreted as indicative of future results. The Company intends to present the complete dataset from the Phase 2a study at a future medical conference and to publish full results in a peer-reviewed medical journal.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has begun planning for a double blind, placebo-controlled, dose ranging Phase 2 trial in Parkinson&#8217;s disease, and potentially in additional neurodegenerative disorders such as Alzheimer&#8217;s disease.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward Looking Statements</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company&#8217;s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the Company&#8217;s plans to present the complete dataset from the Phase 2a study at a future medical conference and to publish the full results in a peer-reviewed medical journal and the Company&#8217;s plans with respect to a double blind, placebo-controlled, dose ranging Phase 2 trial in Parkinson&#8217;s disease, and potentially in additional neurodegenerative disorders such as Alzheimer&#8217;s disease.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans or anticipated outcomes will be achieved. Actual results may differ from those set forth in this Current Report on Form 8-K due to the risks and uncertainties associated with clinical development, including that the Phase 2a study is a short-duration open label study in a small group of patients (and that results observed in the study may not be indicative of future results in a larger study with longer duration), and that the top-line data above has been reported in a summary format and is reflective of the Company&#8217;s interpretation of such data, which is preliminary, and has not been presented with the complete dataset, as well as the risks and uncertainties inherent in Company&#8217;s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; disruptions in the supply chain, including raw materials needed for manufacturing and animals used in research, delays in site activations and enrollment of clinical trials; the results of preclinical studies and clinical trials; early clinical trials not necessarily being predictive of future results; interim results not necessarily being predictive of final results; the potential of one or more outcomes to materially change as a trial continues and more patient data become available and following more comprehensive audit and verification procedures; regulatory developments in the United States and foreign countries; economic uncertainty in global markets caused by, among other things, geopolitical conditions, tariffs, military conflicts, and inflation volatility; unexpected adverse side effects or inadequate efficacy of the Company&#8217;s product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; the Company&#8217;s ability to obtain and maintain intellectual property protection for its product candidates; the use of capital resources by Ventyx sooner than expected; and other risks described in the Company&#8217;s prior press releases and the Company&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including in Part II, Item 1A (Risk Factors) of the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2025, filed on May 8, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:13.62%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:85.38%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vtyx-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release, dated June 17, 2025.</span></a></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">VENTYX BIOSCIENCES, INC.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 17, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Raju Mohan</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Raju Mohan, Ph.D.<br/>Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vtyx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left; margin-left:0; margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img90346216_0.jpg" alt="img90346216_0.jpg" style="width:182px;height:57px;"></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson&#x2019;s Disease</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson&#x2019;s disease</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CSF and plasma exposures reinforce VTX3232&#x2019;s potential as a <br>once-daily oral therapy for neurodegenerative diseases</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">VTX3232 treatment resulted in significant reductions in NLRP3-related biomarkers in <br>CSF and plasma, demonstrating sustained target engagement</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAN DIEGO, CA, June 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (&#x201c;Ventyx&#x201d;, the &#x201c;Company&#x201d;), a clinical-stage biotech company developing oral therapies for autoimmune, inflammatory and neurodegenerative diseases, today announced positive top-line results from its Phase 2a study of VTX3232, a novel, CNS-penetrant NLRP3 inhibitor, in patients with early-stage Parkinson&#x2019;s disease (NCT06556173).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The study accomplished the primary objective of demonstrating safety and tolerability, with no drug-related treatment-emergent adverse events (TEAEs) observed throughout the dosing period. The trial also met pharmacokinetic and pharmacodynamic endpoints, demonstrating high drug exposures in plasma and cerebral spinal fluid (CSF) as well as clear evidence of target engagement in plasma and CSF, with potent suppression of NLRP3-related biomarkers.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;We are thrilled that our Phase 2a data show that a once-daily dose of VTX3232 can safely maintain plasma and CSF levels above the IC</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for IL-1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for 24 hours in patients with early Parkinson&#x2019;s disease,&#x201d; said Mark Forman, MD, PhD, Chief Medical Officer. &#x201c;In addition, we observed biomarker changes in CSF and plasma that reflect potent NLRP3 inhibition by VTX3232.&#x201d;</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">David Russell, MD, PhD, Principal Investigator on the trial and member of the Yale University Parkinson&#x2019;s Disease Research Group, remarked, &#x201c;This was a thorough and well-conducted trial demonstrating clear evidence of target engagement in the CSF and plasma, with significant reduction to near-normal levels or the limit of quantitation (LOQ) in downstream biomarkers of NLRP3 inhibition, including IL-1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, IL-6 and high-sensitivity C-reactive protein (hsCRP). Our investigators also noted clinically significant reductions in MDS-UPDRS Parts II and III. With the caveat that this was a small, open-label study, all patients reported a subjective sense of improvement. Exploratory microglial PET imaging revealed no acute changes - not unexpected given the short duration of the trial.&#x201d;</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Neuroinflammation is recognized as a potential trigger for neurodegenerative diseases. By inhibiting NLRP3-mediated cytokine production and inflammatory markers in the CNS, VTX3232 provides a unique opportunity for a disease-modifying therapy for Parkinson&#x2019;s disease,&#x201d; said Raju Mohan, PhD, Chief Executive Officer. &#x201c;We are delighted that this trial met its goals of establishing that treatment with VTX3232 was safe and well tolerated, with high exposure levels in CSF and clear reductions in NLRP3-related biomarkers in a Parkinson&#x2019;s disease patient population. We have initiated internal and external planning discussions for a placebo-controlled Phase 2 trial in Parkinson&#x2019;s disease and potentially in additional neurodegenerative disorders such as Alzheimer&#x2019;s disease.&#x201d;</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The single-center, open-label Phase 2a study evaluated a 40mg oral daily dose of VTX3232 in ten patients with early-stage, idiopathic Parkinson&#x2019;s disease over a 28-day treatment period. The primary objective of this study was to evaluate safety and tolerability. Key secondary objectives included characterization of VTX3232&#x2019;s pharmacokinetic profile in plasma and CSF, and its pharmacodynamic activity, by measuring effects on plasma, and CSF biomarkers of NLRP3-inhibition at Day 28, including IL-1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf062;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, unbound, biologically active IL-18, IL-6, and hsCRP (Tier 1 biomarkers). The study also incorporated exploratory markers of neurodegeneration (Tier 2 biomarkers), motor and non-motor aspects of Parkinson&#x2019;s disease as measured by MDS-UPDRS, and a microglial PET imaging assessment using [</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F]-DPA 714 binding to translocator protein (TSPO).</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left; margin-left:0; margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key takeaways from the Phase 2a study in Parkinson&#x2019;s patients:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VTX3232 was safe and well tolerated through the 28-day dosing period</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All adverse events (AEs) were mild or moderate in severity and assessed as unrelated to study treatment; no serious adverse events were reported</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The majority of AEs were attributed to PET-tracer administration or lumbar puncture for CSF sampling, and self-resolved</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VTX3232 demonstrated an excellent pharmacokinetic profile</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Steady state concentrations in CSF and plasma exceed the IC</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for NLRP3 inhibition by &#x2265;3-fold for a full 24-hours post-dose</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">High correlation between plasma and CSF exposures between this Phase 2a study and the Phase 1 study in healthy volunteers, reinforcing the profile of VTX3232 as a potential once-daily, oral therapy for neurodegenerative diseases</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VTX3232 demonstrated target engagement by decreasing biomarkers of NLRP3 inhibition, IL-1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in plasma* and IL-18, in both the plasma and CSF (Tier 1 biomarkers) </font></div></div><p style="margin-left:13.6%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insufficient samples above the limit of quantification (LOQ) to quantify IL-1</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Symbol',serif;font-style:italic;font-kerning:none;min-width:fit-content;">b</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in the CSF</font></p><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Downstream biomarkers, specifically IL-6, hsCRP and SAA, were also reduced, and in some cases, approached the LOQ</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effects on biomarkers in early-stage Parkinson&#x2019;s patients were consistent with those observed in healthy volunteers in the Phase 1 study</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tier 2 exploratory markers including sTREM2, GFAP, S100B, NfL, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">Ab40</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42, were either unchanged and/or fluctuated within normal levels</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VTX3232 treatment was associated with improvement in both motor and non-motor symptoms of Parkinson&#x2019;s disease, as measured by MDS-UPDRS</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statistically significant reductions in Part I (p&lt;0.05), Part II (p&lt;0.01) and Part III (p&lt;0.01) were observed</font></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Per the Principal Investigator, Dr. Russell, &#x201c;Encouraging results, with the usual caveats associated with an open-label study.&#x201d;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No acute changes in exploratory PET imaging were observed, consistent with a relatively short, 28-day study</font></div></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ventyx intends to present the complete dataset at a future medical meeting and to publish full results in a peer-reviewed medical journal.</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These data meet Ventyx&#x2019;s internal criteria for continued clinical development in Parkinson&#x2019;s disease.  Planning for a double blind, placebo-controlled, dose ranging Phase 2 trial in Parkinson&#x2019;s disease, and potentially in additional neurodegenerative disorders such as Alzheimer&#x2019;s disease, is underway.</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About VTX3232</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VTX3232 is a CNS-penetrant, potent and selective inhibitor of the NLRP3 inflammasome. VTX3232 has an excellent non-clinical </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> safety profile including in 6- and 9-month chronic toxicology studies.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VTX3232 has completed a Phase 1 trial in healthy volunteers and has shown good safety and tolerability with once-daily doses achieving therapeutic CSF exposures and significant reductions in NLRP3-mediated biomarkers in plasma and in the CSF.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left; margin-left:0; margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors with topline results expected in H2 2025.</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About Ventyx Biosciences</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases. Our inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For more information on Ventyx, please visit our website at </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://ventyxbio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ventyx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Ventyx&#x2019;s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the potential of VTX3232 as a disease-modifying therapy for Parkinson&#x2019;s disease and additional neurodegenerative disorders such as Alzheimer&#x2019;s disease, the anticipated timing and results of future clinical trials, including the topline results of the ongoing Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, management&#x2019;s plans with respect to a double blind, placebo-controlled, dose ranging Phase 2 trial in Parkinson&#x2019;s disease, and potentially in additional neurodegenerative disorders such as Alzheimer&#x2019;s disease, and management&#x2019;s plans with respect to future presentations and publications of VTX3232 data.</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The inclusion of forward-looking statements should not be regarded as a representation by Ventyx that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with a short-duration open label study in a small group of patients (including that results observed in this study may not be indicative of future results in a larger study with longer duration of dosing), and risks and uncertainties inherent in Ventyx&#x2019;s business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; Ventyx&#x2019;s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; disruptions in the supply chain, including raw materials needed for manufacturing and animals used in research, delays in site activations and enrollment of clinical trials; the results of preclinical studies and clinical trials; early clinical trials not necessarily being predictive of future results; interim results not necessarily being predictive of final results; the potential of one or more outcomes to materially change as a trial continues and more patient data become available, and following more comprehensive audit and verification procedures; regulatory developments in the United States and foreign countries; economic uncertainty in global markets caused by, among other things, geopolitical conditions, tariffs, military conflicts, and inflation volatility; unexpected adverse side effects or inadequate efficacy of Ventyx&#x2019;s product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Ventyx&#x2019;s ability to obtain and maintain intellectual property protection for its product candidates; the use of capital resources by Ventyx sooner than expected; and other risks described in Ventyx&#x2019;s prior press releases and Ventyx&#x2019;s filings with the Securities and Exchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of Ventyx&#x2019;s Quarterly Report on Form 10-Q for the quarter year ended March 31, 2025, filed on May 8, 2025, and Ventyx&#x2019;s subsequent filings with the SEC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Ventyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left; margin-left:0; margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Relations Contact:</font></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joyce Allaire<br>Managing Director</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LifeSci Advisors<br>IR@ventyxbio.com</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img90346216_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img90346216_0.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "" :(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBL7Q)XCT/PAH&L^*?$VJ6FB^'O#^FW>KZSJU_*(;33].L87N+
MJYGD.2$CB1B%4-)(VV.-'D95-0A.I.,(1E.<Y1A"$(N4YSDTHQC%)N4I-I1B
MDVVTDKDRE&$93G*,(1BY2E)J,8QBKRE*3LE%)-MMI)*[T&>)O$_A[P9H.I^)
M_%>L6&@>']&M7O-3U;4[A+6SM+>/J\DKD99V*QPQ(&FGF=(88Y)71&_&OXV_
M\%,=>U_4;SP[\";%-"T.*22#_A--7M8KG7-2"ET,^FZ9<QRV6DVL@VR1-=Q7
MM^\9#.NG3!H5^%OVOOVU/$7[4'C6;2=!FOM&^$'AZ^DC\,Z"9)()-:EA>2(>
M)=?A1@LVH7:$M:6D@>/2+206L.9Y+VZN_G[PTO\ J_I^I 'X]S7]"<*^&.&R
MW"TLQXCH0Q68U8QJ4\NJVGAL%%I2C'$0^'$8FW\2,^:C2;<%"<X^T/P'B_Q(
MQ>,KU<!P_7EA,!3DZ<\?2;CB<9);NC/26'P]_@E#EKU4E)SA!NF_J?5OB=\1
M_B%]L'BWQYXOU7[>H\POXBU:,V\BL7BGL!'=*MA/!*%G@DM%A\N5$8#Y<'#^
M%W[=W[1_[*OCZV\,>-/$NK?%GX;J\#?V1XOO9M0O[G099&"WNA>([O[1JFGZ
MG;*6@:":XO-+6>!X9=/93%,F1X?4 K^.,CG&2/\ /UK&^./@-?%_@*YU6TB#
MZSX3275;5E7,DVFA<ZM9Y&2R^0BWT:D?ZRT*K@RG/TF-R[*\1%X/%X#"5,)4
M7L_9NA3C&G=J,947",9491=K3I.$HIW4E8_D+QRRWC=\.U/$/PZXESW(/$7@
M>E5SC XW+,=B(RSO*<)?$YGD.;824ZF%SK"SHPJ8W"X',L-C*%3%4I86-'DS
M#$\_].WPB^+7@GXW^ - ^)'@#5$U3P]K]MYB9*+>Z;>QX6^TC5;97<V>IZ=,
M3#=6[,1]R>%Y;::":3TJOY??^"7?[3MS\(?C%;_"_P 1ZE(GP]^+%W;:2(IY
M?]$T7QG(5M_#^K1+(P6$:C,T>A:@4"^;%=V5S<%DTN%5_J"K^>^*^'JG#F:U
M,(G*IA*T?K&!K27O3H2;3A-I*+JT)J5.I9+FM&IRQ5117]6_1:\?,%](3PNP
M/%4Z6&P/%.4XAY%QIE.&<E1PF>8:C3JK&8.G4E*K'+,XPM2EF&"4Y5/82J8G
M+G7Q%; 5JLBBBO(-=_:$^ ?A?6-0\/>)OCA\(/#NOZ3.;75-#UWXE^#-(UC3
M;H(DAMM0TS4-:M[VSG$<B.8;F".0(Z-MVL"?GZ.'Q&)DX8>A6Q$XQYI1HTIU
M9*-TN9QIQDU&[2NU:[2W9_1[E&/Q-*^BNTKOMJ>OT5X5_P -1?LS?]'%? K_
M ,.YX _^:"KNF_M(?L[ZSJ%CI&D?'OX+ZKJNJ7EMI^FZ9IOQ2\#WVH:C?WLR
M6UG8V-E:Z[+<W=Y=W$D<%M;6\4DT\TB11([NJGH>5YG%.4LNQRBDVV\)B$DD
MKMMNG9)+5MZ)"YX?SQ_\"7EY^:^]'M%%%<WXK\9>$/ >CR>(?''BOPWX,T"*
M>"UEUSQ7KFE^'='BN;I_+M;>34]7NK.R2>YD^2")IQ),_P L:LW%<<(3J3C3
MIPE4J3DHPA"+E.<F[*,8Q3<I-Z))-M[#;25VTDMV]$OF=)17A7_#47[,W_1Q
M7P*_\.YX _\ F@I1^U%^S.3@?M$_ HD] /BYX )/X?\ "05V_P!E9I_T+<?_
M .$>(_\ E9/M(?SP_P# E_GYK[SW2BHX9HKB**>"6.>">-)H9H762*:*10\<
ML4B%DDCD1@Z.C%74AE)!!K)\0^)/#OA'1[[Q%XKU[1?#'A_2X&N=3UWQ#JEC
MHNCZ=;(,O<7VIZE/;65I @!+2W$\<:@9+ 5Q1A.<E"$92G*2C&$8N4I2;LHJ
M*3;DWHDE=O1(NZM>^F]^ENYM45^9?B__ (+(_P#!,OP3JT^BZQ^UW\-[R_MI
MF@G_ .$8M_%/C*P21&VMC6/"?A_6='F0'^."_E4CE21@U[)\%/\ @HI^P[^T
M3JL&@?![]I[X3>+O$=T56S\,OXCC\.^)KYW( CL/#GBJ+0]:OY<D9BLK&=U!
M!*A2#7OXCA'BO"X5X[%<,<0X;!*'M'C*^2YE1PJA:_.\14PT:2A9I\SFDUK>
MQA'$X:4N2.(H2G>W+&K3<K]N52;O\C[0HHI"0 22  "22<  <DDG@ #J:^>-
MQ:*\A\??M!? ?X56\MW\3?C3\*/A[! C22/XT^(7A/PR0J@D[4UC5K.21B =
MJ1H[L>%4GBLWX'?M*? ;]I;2/$>O_ /XJ>$/BOHGA+7O^$8\0ZOX-U'^U-.T
MW7?L-KJ0T^2\2-()Y#8WEM<++:O/;NLFU9BZ2*G;_9N8_5)X_P"H8WZA3<(U
M,;]5K_5(2J2Y:<9XGV?L8N<FHP4IIREI&[T(]I#F4.>'.[VCS+F=E=VC>[LM
M7IL>X45S7BWQIX.\ Z+=>)/'7BSPUX+\.V*%[W7O%FNZ7X=T:T0#):YU35[J
MSLH% [RSJ*_/'Q;_ ,%D/^"97@O4)M+U;]KWX:7MY;RF&4>%XO$_C*T5U;:2
MNI^$] UG2Y4!Z/#>R*P^9"PYKIRW(<]SGF63Y+FV:\CM/^S<NQF.Y&^D_JM&
MKR_]O6%4K4:7\6K3I_\ 7RI&'_I31^F=%?+W[/O[:O[*/[52W:_L^?'GX=_$
MZ_L(OM%_H.AZTMOXILK;O=W?A/5X]-\2V]F"0IO)=*6U#_)YVX@5]0UQXW X
M[+<1/!YC@\5@,72M[3"XW#UL+B*=U=<]"O"G5A=:KFBKK5%0G"<5*$HSB]I0
MDI1?HTVF%?CC_P %GO\ @I)XR_X)R? KX?>)?A7HW@OQ#\5OBGX[N?#7A_3_
M !S;:GJ&C6'AW1-$N-2\3>(#IFD:SH5[>3V-W=>'=/@#7ZVL<FKB2>&<*J5^
MJ?BCXI_#'P1?0Z7XT^(W@/PAJ=Q:K>P:=XH\7^'] OI[-Y)84NX;35M0M+B2
MU>:":);A(VB:2&6,.6C<#^#3_@Y$_:=T+XY?MI>%/AOX*\3:3XH\%? GX8Z3
MI*ZAH&K6NL:+/XQ\=2_\)9XCGL[VPGN+">2/1Y?"6F7;P3.8[G3);679+;NM
M?JG@MP73XNX[RK"YI@)XG),+0Q>:9A"M2JK#XC#X:DZ="E*:Y%.%7'5L)"<5
M+WJ;FM5<\_-,4\-A)RIS4:LI1IP::YDY.\FEW4%*SZ.S/ZNO^"._[6WQ;_;8
M_8OT;XZ_&V[T"[\>:E\1?B#X?NCX9T2'P_I%OINA:C;1Z5:6^GQ37!!@M;@*
MT\\\MQ,"K322,-[?J97\X/\ P;I?&'X6>$O^"=-KH7C'XF?#_P *:M:?&[XF
M,NE>)?&?AW0]1^R7-KX6N8;G[#JFI6MR+>9Y9A%+Y7ER-')L8E6 _=[_ (:%
M^ 7_ $7'X/\ _AR_!?\ \NZ\'Q&R*67\=\6X++<KJ8?+\-GN84L'0PN$J1PU
M'#QKR]E3H1IPY(TH0M&"CHDK(VP-7GP>&G.IS3E1IN<I27,Y.*NW=WNWJ>P4
M5YQK_P 8_A%X4TG0M>\4_%3X<>&M#\412S^&=9U_QQX9T;2?$4,*0R33:%J.
MHZI;6>KQ0QW%O)+)I\UPD:3PLY"RH6Y'_AJ+]F;_ *.*^!7_ (=SP!_\T%?%
MT\NS"K'GI8'&5(7E'FIX:O./-"3C*/-&#5XR3C)7O&2:=FFCJ<X+1RBGV<DO
MU\U]Y[K17A7_  U%^S-_T<5\"O\ P[G@#_YH*];\.^)?#GB_1K'Q'X2U_1/%
M'A[4TDDTW7O#NJV.MZ-J$<,TMM+)8ZIID]S8W:17$,UO(T$\BI-%+$Q$D;*(
MK8+&8:*GB,)B</"4N53K4*M*+E9OE4IPBG*R;LG>R;M9,%*,MI1?HT_R]4;5
M%%>(7'[37[-UI<3VEW^T'\$+:ZM9I;>YMKCXK^ X;BWN(':*:">&37UDAFAD
M5HY8I%5XW5D=0P($T,+B<2Y+#8>OB'"SFJ%&I5<%*_*Y>SC+EO9VO:]G;9C<
MHQW:5]KM+\SV^BO"O^&HOV9O^CBO@5_X=SP!_P#-!76V/QD^$.I^%=4\=Z;\
M5?AOJ'@C0[I;'6O&5CXY\,7?A72+US:A+/5/$,&J2:1I]TYOK$+;W=Y#*QO+
M4!#]HAWZSR[,*:BZF!QE-2G&G%SPM>*E.;Y80BY05YSDU&,5=R;LDV)3@]I1
M>E]))Z=]]CTBBO"O^&HOV9O^CBO@5_X=SP!_\T%'_#47[,W_ $<5\"O_  [G
M@#_YH*O^RLT_Z%N/_P#"/$?_ "L7M(?SP_\  E_GYK[SW6BN/\&_$+P#\1K&
MZU3X>^./!_CO3+&[^P7NH^#?$VB^)[&SOO)BN/L5U=Z)>WUO;W?V>>&?[--(
MDWDS12[-DB,<[QG\6_A5\.+FQLOB'\3?A]X#O-3@ENM-M/&?C/PYX7N=0MH)
M%BGN+&#7-2L9;N"&5TCEEMTDCCD94=E9@#SK"XF59X:.'KO$*Z=!4:CK)I<S
M3I*/.K1]Y^[HM7H5S1MS<RL]G=6^_8]!HKPK_AJ+]F;_ *.*^!7_ (=SP!_\
MT%=%X6^.?P3\<ZQ#X=\$_&+X6>,?$%S%<3V^A>%OB#X2\0ZQ<0VL33W4T.F:
M3J]W>RQ6T*M-<21P,D,2M)(50$C:>6YC3A*I4P&-A"$7*<YX6O&$(Q5Y2E*5
M-*,4M6VTDM6Q*<'HIQ;>R4D[_CYK[SU.BBBN(H***\3^('QKT7P=<2:980+K
M.K1';/&LPCM;5@VUDDD17:69/FWQ+Y:*RM&TZRJR#IPN$Q&,JJCAJ4JM2UVE
M9*,5O*4I-1C'I>32;:2NVD>=F>:Y?D^&>+S+$T\-04N6+ES2G4FTVH4J<%*I
M5FTF^6$9-13D[13:]LHKY3\._M.:=<:G%8^)M+CT^VN'"+J-F\A2W+-@&:VE
M>=Y(U'S.\<RR <1P2MA:^J(9HKB**>"1)H)HTFAFB97CEBD4/')&ZDJZ.C!D
M92592""0:TQF7XO 3C#%4G3YTW"2E&<)I6ORRBVKJZO%M25TVK--\N3<191G
M].M/*\9#$/#RC&O2<9TJU%S3<'.E4C&:A/EER5$G3DXRC&3E&24E%%%<1[85
M_.9_P5;_ &T)?%?BN?\ 9A^'&L,/#'A6[C?XIZE82D)KGBBW99K?PIYZ';+I
MOAN15EU.-2R3Z^!;R;)-$'F_J7_P4(_:NM?V3?V?=;\4:==0#XC>,'E\(?#2
MRD'F.NO7UNYNO$#P@Y:T\,6!DU-RX\B74/[+L)BHOU-?QT:1?7FJ7MQJ>HW,
MUYJ&H74][>WES(\]Q<W=U*TL]Q/-(7DEEFE=I))9&9Y'=F9F9B3^_>#/!,<;
M4J<79E1YL-@JLJ&3TJD;QK8V"7ML;9Z2A@[JG0=FGBI3FG&IA5?\;\4^*I86
MC'AO U7&OBJ:K9G.#M*GA)/]UA;IW4L4TYUEH_J\8Q:<,0[>X>&5X3'0 '\0
M!^O3->]^&T_U?7. >W7CC^=>%^&5&U>O.,?3"@YS]>,?RKWOPTC'R\ GA3CG
M.?3&.OM7[9F;UETUM;_P%^?=GX1#9^OZ(]K\/J3M_#\OFS7LVBPQ3;X9HUE@
MEC:*:)P"DL4P*2QNIX9'1F1AT()!KR30+:<&,&&49PH!C<$]>GR_2O9=$BD1
MU61'0C'#J5/WN.& ..G;I7P68.W,VO\ .VCMZW1T1Y91LU&2::<9)2C)/=-.
MZ::=FGHT]=S\J?&.AW7@+XB:]H]F\]O-X?\ $$QTV:*1XIX[=;@7>F3Q2H0Z
M2"U>VD25""&PR\XK^PO]E[XK_P#"[/@-\-OB'//'/JVK>'K:U\2;.-GB;2-V
MEZ[N7"E!/J%I->0J57-M<P. %<5_+]^T?X9C3XJ1ZDB #6?#NDW<A'0SVIN=
M.D8C'+&*TA!)/.!QCFOV*_X).>-7D\#?$#X9W4SLVB:O9>*])C?!Q::O;IIN
MJ)'@ ".WN-.TUR #^\O7)P"N?B/$3#0Q_#V%QRC?$9?4IU')*[]CB%"A7C==
M/:^PF^B4'\_XX^A9BL1X4?2F\2?#9571X:XNQ&?Y7@,(W*-*.,R#$XK/.&<0
M[OD]I'(ZF:X.*6LYXVG%.344?KI7\O'_  4I_P"#>SQ#^U;\<?BO^TY\$_CU
MIOA[QK\2+N+Q%J?PS\=>&IT\/S:Q8>'M-T@6^C>,-#O9+G3EU2325N7&I>'+
MY5O;Z9I+V*!<K_4/17YGPCQIQ%P-F<\VX;QL<%BZV'>$Q'/A\/B:6(PLJM*O
M*A5I8BG47)*K0I2YZ?LZL7'W*D;N_P#LEB<+1Q<%3KPYHJ2E&TG%QDDTFFFN
MC>CNO+8_Q]]=TC6?#.MZQX;UVUNM,UOP_JFH:+K&FW0>.YT_5-+NY;'4+*XC
M)S'/:W<$L$R$ I)&RD @U_6K_P $;O\ @B)I7C&U_9C_ ."@'C3]H'1]>T"#
M5M ^*WA'X8>#_"]Q=XUSPIKDVW1?%_BC6KVVCMKS0_$FD26FIV6E:!=*MWI\
MAM-7='CG'YC?\%^?V6E_9O\ ^"@OCSQ#HUB;7P1^T+86_P :O#OEPK':P:SK
MUS<V/CW3HVC58S)%XRL-4U?RE ,%EKE@ISD,?V^_X-=/VF?^$I^"_P ;?V5=
M;O0^I_"WQ/:?$_P3!*_SOX0\=J--\265JC,3Y&C>*=*@U&;8H43^+B6"LV7_
M +>\4>+<^S'P>PW%_"&/>#HYAA<OK9O&%"AB)_V5FM*6!Q^%A.O2JRH5<+C\
M12H5:U'DJTXTZ[52+7,OEL!AZ,,R>&Q,%)PE.-/627M:;4X2:35U*$>:*EH_
M=TZ']5U?'_[=W[('AG]NK]F?QS^SAXJ\3ZCX*LO%MUX<U2Q\6:3IUIJU_H6K
M^%]>L-=L+J+3KV6W@NHIVLI-/O(A<VLQLKRX^SW,,VR1?L"HIYX;:&:YN98X
M+>WBDGGGF=8XH88D,DLLLCD)''&BL[NQ"JJEF( )K^!,MS#&Y5F&"S/+J\L-
MF&7XJAC,%B(1C*='%8:K&K0J1A.,X3<*D(RY)PE"5N6491;3^OG"-2$J<US0
MG%QE%W5XM6:NK/5=FF?Y>?\ P4H_8(U/_@G5\>--^"&I_&#PU\7+[5O!UAXW
MBO\ P_I&J^'[_1M+U;5-5T[3++Q'I%_/?V]EJEW'I,M]'#8:QJD)LIK>9YHV
MF6,?KY^PK_P;?^.OCW\,OA-\>_C;\>K#X<^$_B+X:T'Q]I?P_P#"_A&\\0>,
M_P#A'];CCU+2(M:U37+W2-&T:[U#2I+:]:"#3_$"10WL44Q2:.:(?G7\1]1U
M?_@JS_P5_O;/3KJ[O_#WQN_:#L?">B3Q/)(=+^"_@VYATB+4+9=CBW2Q^&WA
MJ?6YE"+']L-S*XWRN3_I+:+HVF>'=&TGP_HEG!IVC:%IEAHVD:?;(([:PTS2
M[6*RL+.W0<)!:VL$4$2#A8T4#I7]F>+'BAQIP3PSP3D]'-H4>,,VRB.9<1XU
M8' NK0C*E3I^QI8>=">%HRJ8N>*H^UI8>,E]0<H<CJ,^8R[ 87%5\54=.^&I
MU.2C'GE9ZW3<DU)VBHNS=O>6]CY-_;*_:^^#O_!/_P#9SUGXR_%"Z=M*\.6=
MIX;\$>#["6&/7_'GBQK)XM \(Z%')\BS7*6CW&HZ@\;6FC:1:WVJW2M#:^5)
M_!WXK^-'_!0O_@NC^T]:?#+2=3O;K3+^YGU?2/ACI.JZAH7P3^$'@^PN(%F\
M2>((@\L-RVF"6V2[\3ZO!J?B;6-2N(-.TF)I;O3M'C]9_P"#AG]L75OVA_VW
M=<^#6D:I(_PQ_9?2?X?:1I\$[&ROOB!<I:W?Q'UZXB25HI+Z#58[;PE&SH&@
MMO#.8MAO+GS/Z"_^#;3]E_1OA+^Q'<?'N^TN!?'O[2'BS6=3?59((A?6_P /
MO ^IWWA7PQHT<VSS4M9M9LO$VONJR;+@:I9F1=UK'M\+(<HR_P &?#"EXAXW
M+\-F''/$*PL,E>/IJK3RMYI2J8G!TZ4;J=.I#+Z57'XZI!TZ]6I;+_:4J7-.
M6U:K/,\>\'"<H82CS.IR.SJ*FTIM]&G-J$+WBE[]F]#YT^&W_!J]\!K/PM9I
M\7/VE?BKK_C62T3^TKCX?:)X4\,^&+6]9<R)I]KXAT_Q1JMW! Y*1W%U=VC7
M**)'LK9G\I/QD_X*F?\ !%+XG_\ !.S2M/\ C5\/?&M[\6O@%/K5EI5SXK;3
M%T/QG\.-;NW4:+%XML[&YGM)]/U.Z0V^F>*=*:UM1J?D:=?6&F75UIG]H?Z)
M=?+O[;7PFT3XY?LB?M(_"K7[9+JQ\7_!OQ]9VX=58VNM67A^]U7PYJ46X$+<
M:5X@L-,U*W<#<D]I&RD$ U^?<)^/?'^%XGR_$9YG<\VRG%8ZA1S/+Z^$P5.B
ML)B*T:=:IA/J^&HSPU;#PDZM#V4XTY3A&%:%2G*2?9B,HPDJ$XTJ7LZD8-TY
MJ4V^9*Z4N:34E)Z-M72>C1_+9_P0;_X+%_$;4/B3X6_8G_:E\::AXUT3QF5T
M7X&_$GQ5?7&H>)M"\4QQLVG_  ]\1:[>22W>M:+XACC-CX6N]2FFU'2]:%EH
MB7%QIVIVD6E?T+_\%3_V4OCA^V3^RI>_!S]GWXC:=\,O'[>.O#/BG^VM5\0>
M)O#-AJ>B:+::W!J/A^?4_"MG?Z@HU"34;2=(+BTETZ62R3[28V6*5/\ ,>\*
M^)-7\%^*O#OB_P .WDEAKWA77M*\1:'J$3.DUEJVB:A!J.FWD31LDB26UW;0
MS(R,CJZ JRD C_6X^#GCR'XI_"+X6?$ZW54@^(OPY\$>.H43E8X_%OAG3-?2
M,>R+J 3'48P>:^P\>^&Z' '%_#7'?#.&PF"J9AB:U>MA5AJ4\##.,KGAZT<3
M]5:5'EQU+$)UJ48J$JV'JUG^\KSD<V45WC,/7PM>4IJ$8J,N9J;I337+S;^X
MUH^TDMD?YD/[=/\ P3Q_:K_8-UGPC_PTMINAK_PLR7Q$_A3Q%H/C.P\76WB%
M_##:4-9DE:.9=7LY(!K>FL!J]A9R3"X/E"3RY-OJO[ W_!53]H7]@3X7?&/X
M5_ 'POX6U;Q)\:?$?A/5=-\2^);&_P#$$_A#4-&L-6TFX?P_X6MY8+#5=7UJ
M/4M/CCEU0WMI ^EVZ-I5_P";M3]QO^#KK_4?L3_]=/CM_P"@_"FOF#_@UV\"
M^"_%/[5'QVU_Q+X3\/>(-;\$_![3-4\'ZKK6D6.IWWA?4[[QEIEC=ZEH%Q>0
MS/I6H7%D[VDE]9&&Z^S/) LRQ2RJ_P"PT>,J'$7@:^,^,\CP&>0A1JXO%Y-1
M4\)@<76RWB*>"P$;5)XETJ:JT,-5KQE[:G/EJQ=&=.?L'YKPSH9J\+A:LZ3O
M&,:KM*<54H*4_A4;NTFHVLTK:W5SYL;_ ()W?\%K_P#@I!=0?$[XNZ!\3=7L
M=4VZEI&J_M ^-;/X?Z/;0W2DI+X<\ ZQ=V=YH6GO"X:!=$\&6-C);NGV59(@
M0O/?$K_@WD_X*9?#OP_?>(;+X:^"_B1#I]L]U/I7PY^(.BZMXA>.-"\JV6BZ
MN-"O-3G50WEVFEK>WERX\JVMI97CC?\ T7:*_GZG]);C+"5*5+*\CX3RW*<.
MU'#Y3A\NQ4:-.@GI2YZ6.HJ,K:<U"E0A?54DO=/8>1X:2;G6Q$ZDM95'.%V^
M]G!Z/K=M_P!X_P B3PUXH^*7P$^)%GX@\,:MXP^%7Q3^'GB!F@O;*74_"_BW
MPKXAT>Z:*XM;B,_9;^PO+6XBDM;^PNXUW 3V=Y T;RQ-_I'?\$A/V^Y?^"@?
M[)>C_$#Q5_9]O\8_A_JK_#WXPV6G0_9+2[\1V-G;WFF>++&Q "VECXOT:XMM
M2:"#-I:ZS%K>GV>+>Q1%_F._X.>?@/X2^'7[6WPF^,/AC3+32;[X\?#349O&
M45E##;IJOBWX>ZM:Z/-X@N$AC0-?7_A_6/#EC=3N6DN'TH3RLTLDC'W_ /X-
M3/$FIIX^_;"\("=SHUUX/^%7B-K;<WEKJ=AK?B[3$G"9V[WM=3>,M@,%C R0
M>/UGQ7AE'B/X,8/Q"A@883,L#A\%C\-.\9UZ$:N9T\JS3+)8A1C*MA8XBI5J
MTN:,7*IAZ-50IN=2+\_+W5P69RP;ES0FY0DMD[0=2G4Y=;2M9/7:35W9'V7_
M ,%IO^"0G[4W[?W[2O@/XM? _5/AC8>&/#?P<T;P'J*>,_%&I:'JCZUI_B[Q
MEKDS0VUGH.J1RV/V/7[,13-.CF?[2AB4*KO_ !Q?M9_LP?$7]CCX\>,_V>OB
MM=>'KSQUX&C\/R:S<>%M1GU;1''B3PYI/B>P%I?7-G833,FG:Q:+<![6(Q7(
MEB&X)N/^LC7^;A_P7W_Y2I_M)_\ 7#X3_P#JG? 5>+]'+Q"XASG,8\$XV6">
M29'PUB<1@52PSABU4H9CE]&G[6O[62J1Y,;7YE[.-WR.ZY7?3.L'0I0>*BI>
MUJUTIMR7+9PDW:-M-8K6_K?IS_[%?_!&7]K3]NOX,-\<O@OK'PLLO!R^+M;\
M&F#Q?XLU/1M7_M;0;;2[J]?['9^']3B^RM'JUKY,IN0[L) 8U"J6^M_^(9K_
M (*'?]#%\ __  X6N_\ S'U^]_\ P;2?\HWIO^S@?B;_ .F7P+7]!->'QYX^
M\?\ #O&7$F19=/)U@<JS;%X+"*OETJM94*,^6'M*GUF//.V\N6-WT6QK@\HP
M=?"T*U15.>I3A.5IV5VDW9<NBT[_ #T5OP%^.W_!&/5OVJ/^"?'['/[,?CSX
MJ67PO^+O[+?@F#3+;Q'H.BCQKX2U'6KK0;#2=:TZXCEN_#FIR:1<2Z7I\\5[
M:3P3(T.Z2SN<(B_Q%_MK_LB_$W]AG]H?QC^SO\4;W3=5UWPQ#I&J:;XDT!KW
M^P?%7ASQ!IT.I:1KVD?;X+:[6"5)9;*[@GA62RU6QU"P9I6M3(_^K=7\FG_!
MT3^RD-?^'/P9_;#\.V!;4O .IM\(?B//!&FZ3PMXFGN=7\$:G=LJ!Q%H_B1-
M9T@RLQ#R^*K"$[?+C#<W@5XLYXN+L/PMG.-I3R3B#%9K5PE!8>A2C@L\S+$U
M<S3HUH06(='&XN5?#QP]6K5A&MBZ;AR<KO6;9=2^KO$4H/VM&--2=V^:E"*A
MJF[)PBHR<DD[0=[GX!?\$L?^"9=]_P %+O'WQ \(VOQQ\/?"2#X9Z5H/B'6[
M6^\/ZKXG\4:YH>L7]UI\]WX;TR&\T?2GBTRZ@M;74;B_UNW:UFU?3&CL[M))
M G^B1^RM^SWX;_92_9Y^$_[._A+5;[7=!^%/A6#PW::YJ=M;6>H:U-]JNM1U
M+5[RUL\VUO<ZGJE]>WTL,+.L;SE?,E(,C?YV?_!%_P#:B3]E/_@H-\$_%6K:
M@=/\$?$349?@UX^=Y'2U70/B)+:Z9IU_>8(1+;0_%L7AK7;B>3Y8+;39V8A"
M^?\ 3,J?I/8_B:'$>7Y3C,=.KPOB,+0S;*,(J&'A3HXZE"K@<<IXB%*.(KUJ
M;;JI5:LXTJ..IQC%7NS(84/8SJ1@E74G3J2O*[@^64+)OE2=K>ZE=PU85_"K
M_P %A/\ @B7IG[+'A#XQ?MH^$OVA],N_!FL_$275V^%OBOPM=Z9XB76OB3XQ
MEFM_#?A'7=%O-0T[6$TP:G=7$<6HZ5H?D:'H]W=2W<TT6Q_[JJ_CC_X.F?VE
MC+??L]?LE:+>C99P:E\</'MO%,V3<7;7OA#P!:SQHP7,,$/C.^DCF!RMWITT
M8RN1\5X YAQ+0\0<MRO(<=+"8/-)QJ<00^KX>O3Q&4Y;"KBZL)NO2J2H3G[V
M&HUZ+IU:=7$QM)WL^K.(4)8.=2M#FE3THOFE%QJ3:BFK-)VLI-23347H?AA_
MP31_X)D_%;_@I9X\\=>&? _C?P_\-_"_PST?1M6\9^-?$NGZOK$5LWB&]NK/
M1]*TC2M,\@:GJ]XNGZI>+;7.J:5;)::=.\EXCO"DG]KGP=_X(\_#WX4_\$Y_
MB[_P3\?XKZ_K]A\9M7U#Q/XE^*#>&-+L-1LO$UT_@V>QNM-\._;[R$V&F3^!
M]'\FVN]7FNY(FN5%_ QA:'R7_@W7_9G;X%_L Z/\1=8L!:^+/VD_%.H?$^ZD
MD7%TO@VQ7_A&? =I(2BM]FFL-/U+Q+9+N9/*\3M*I!E;/[TU[7C+XM<1YGQ?
MF.2Y5FBH9#PWGF%J9=3HX?"RE+-\DE!/'SQ%2C.M5]EF5.O.A3=3ZLZ<:;E2
MF]3/+,NH4\-"K4IWJUZ4E-MRTI55\"2:2O3Y5)VYKWU6Q_F2_P#!3#_@EI\:
MO^":_B_PI:>,/$6G_$CX9?$"*^_X0KXH>'M,U'2=/N=3TV1C?^&-?TN]EN_[
M#\2VUDUMJ26::EJ-I?:?<&>POKAK/48;/YD_8O\ V;[+]KO]HKP#^S[??%WP
MO\&+GXAW<VE:'XO\8V.JZGI4^O>7YFF^'K>UTPQ>9K.NNKV>BPWU]I=C>ZF;
M;36U""ZO;59/],+]MS]D3X>?MP?LX>/_ -GWXB11P0>);!K[PEXE6!9K_P $
M>.]-BFD\,>+M-SAC)IMY(8=0MD>/^U-$N]4TB61(;^1A_E__ !K^#_Q2_92^
M.GC+X2^/K.]\)?$[X1^,)-.N)K.XG@DAU#2;J.[T;Q'H.HP^1-)I^I6XL==\
M/ZK 8GGL;JRO(O*9P%_H;PA\3L;XD<,YEEF*S&GE_&N6X:M">,IX;#RC5I5D
MX8'.J6 G#ZM45"O*%+&X54_8JK&F[4H8RE"'C9E@(8*O3G&'-A9R346WHXM.
M=)R3YE=*\)-WL^K@V_\ 2K_X)K?\$_\ PO\ \$YO@#J'P4\/>.=1^)%]XA\<
M:E\0/$WB[4=#M/#SWVMZEHN@:$UM9Z7:WFI/;Z=:6?A^U%JMWJ5]<[I9M\^S
MRXT^:O\ @KK_ ,$I?#?_  48T+P%XPG^-,?P2\4_!/0?&8M-=U;P_;:YX1OM
M"UIM)U;4CXHD.K:)?:5:Z3_8+W":G!>S06<%W?3SV4P1<;__  1H_P""C-C^
MW[^S+9GQ=?VR_M!?!V'2O"/Q?T\R(MQX@)M6C\/?$FTMA@BS\86]G<?VFL:^
M79^)[#68$2&RET[S?RG_ .#BS_@I\?"6BWO[ GP0UX#Q-XFL;.[_ &BO$>EW
M#>=H?AN]2&^TGX76MS;R+Y>H^(X&@U3Q@F28?#\FGZ*XD&MZI#:_S'PYD_B7
MB/&:KA:>-JX/C7#YGBJV<9U/"X:O1PF#G3]CC<SGAYT%@ZN#Q& Q$?J=-4:=
M/$+$X6E1]G.K3<?=K5<"LL4G!2PLJ<%3HJ4HN4DU*%--/F4HSC[[NW'EDW=)
MW_D?T+X+>)_B%\=[3X!_!:^B^,/B/Q%\0)/ /@+5/"MMJ5KIWCF=]5DT[3M<
MTN#6+>QO[#1M0AC_ +5-QJ]M9'3]+\R\U);6*"=H_P"XW_@E)_P0MU+]@GXP
MZ=^T=\3OCAI_C_XCVO@_7O#=EX,\)>&9[/PGH<GBBTMK74KIO$NL7K:KK-U;
M6R7-K;O#H>AQ,EU(7$J *_DW_!O%_P $QE^"?P\MOVV_C/H+Q?%CXJZ'+!\'
M]"U6V"W/@3X8ZHJB3Q1);SQ":T\2>/X!OM),K+9>#7@565O$6H6\/]05?;>-
M_C/F6+QV/X(X9S"+R7#X:ME6?X]4<+5J9SBI+V6-H4JKHN-#"T;2H3J814'7
MKRQ')+ZO&BY<F599",(8JO#]ZY*I1A>25..CBVKW<GHTI-I1Y;ZWL4445_*Y
M] >7?%OQFW@WPI<3VLGEZIJ1>QT]E8*\!9";B[7*OAH$*I$Y4K'<3P.P905/
MYN:MJ[,\TDDC22R,SR2,Q9V8Y/5B3VP!DX  XQ\OOW[3GBSS?%D.BQR QZ-8
MPHZ@L-ES=(+N;C.TB2*>U4X&[= %)X&/C#5M7^]\_KWX[]./7'.>..W7]+X>
MP<<-EU*IR_O<4E7J2ZN,M:,4_P"54VG;^:4NY_+/BAQ2\1GN+PRJOZOE<I8*
MC"ZLJD++%SY=N>>(4J<I;NG2IQUY235M8QN.[ID]>GIT^G3U'TQ^E?[*GC*;
MQ;\+X[>ZE>6Z\-:K=:+OD*EFM##;WUIC;TBB%W+:0KCY8K5%!( K\@M5U?AO
MG)].3QCZ]_3GGG/?/Z2_L$^;-X \97S9,,WBR*WC)SS);:5;22CGN$NX>GJ.
M_3/B:G"65SE)>]3K494WUYG+V;U_P3E?Y,^>\'<]KU?$3#X.E-^RQF6YE3Q,
M$[Q=.E1CBH2:6BY:]&FHMJZ<FD_>9]W4A(4%F("@$DD@  #)))X  Y)/ %+7
MYM_\%5/VI!^R]^R7XPU#1[XVGQ!^*'F_#'P%Y$QBO+2]U^QN1KOB"W9 9(F\
M/>'DO[JVN5 $6KS:0C,GG!A\9DF48O/\WR[)L##GQ>98NCA*.C<8.K-*=6=M
M52HT^:M5EM&G"<GHC^N<SS##Y3E^,S+%2Y:&"P]3$5-;.2IQ;C3CWG4ERTZ:
MZSE%=3^<G_@IC^U<W[4/[47B!-!U(WGPQ^%4MWX#\ K#)NL;\6-UCQ)XGB&Q
M1(WB+68)'M[CDRZ'9:(C -"<_+_@O3[S4KJSL-/M;B^O;V>"VM+.TADN+FYG
MFD6.&""")6DEFFD=8XHHU9W=E1068"O-/@5\+O'?QG\;Z!\//AUX?O?$OBWQ
M)>1VNG:=91@GG,EQ=W4[E+>RL+.%9+F]OKJ2&TM+>.2:XECB1F']DG[#W_!.
MSX=_LJZ)I_B7Q+'I_CGXTW-O%+?^*+BW$VF>%9&B(DTSP;;W";K?RM[Q7.OR
MQIJ>H'=Y2Z?9M]B']F\6<2<.>%V09;DU)>WKX;!4Z&6Y71G".)Q"I)*>,Q4T
MG'#TJU?VE6OB)0<JU>554:=6<:BC_,639!G?'V<XW,)OV-"MB9U<=F%2,I4*
M#FU*.&P\;IUJE.ERPI48R2ITHT_:SIQ<'+\\_P!F/_@EK\2O&VG:?XF^,6HS
M?##0+I(KBWT%;=+OQK?6[@D--92NMKX>\Q0K1G4S/?QEOW^CA0-_[#_#O]C#
M]G3X;V]O'IGP]T[7KR!5W:GXP)\27,TB@?O6M+T'2(79AO/V73+<!N0!@8^I
MJ*_E'/N/>)>(*U25?'U,)AI-\N"P$IX:A&#?PSE"7ML1W;KU:BO=Q4%:*_?,
MEX&X<R2G#V6 IXS$Q2<L9CXPQ-=S27O0C.+HT/)4*=-VMS2DU=\[;^#_  E:
M1+!:>%O#EK"JA5AM]$TR&)5 P%6..U5 H'  &,<5Q/BGX'?"SQ?%(NI^#M'M
MKF12!J.CVD.D:@K9R':>P2%;@J0"$O([F(X :,@8KT'2]9MM7GUB*T^>/1M3
M?2)IPP9);V"UMKB[C0 9'V5[I;:3)/[^*5>-G.O7R\,7C<-54Z>)Q-&JN67-
M"M4C/5*2NU)/5--I^C6Z/HJV R_%T71Q&#PF(H23BZ=7#TJE-VO'2,H-*UM&
MK-;I['\X?[>OPCT[X6?%KP9H%MJXU)-5\'S:GIRW$?DW@M!K6H0>5,!F&6:-
MX)"[1%!*I\Q((@&C3T+_ ()TZV_A?X]:?IK2,EMXL\/ZWH4J$A4,R6RZU;,5
MXW2&XTB*!.I F<D<DCCO^"KFKMJ?[2/AC3K5V6;PQ\.]"B\U#AH;J]U?7=3V
M ]5<07=M+Z,LJ@]ZY/\ 93\4FR^(WPY\1JJQW.G^*=&M]3087RXY;RWBO)E/
M&(IK&29U'N\9/RDU^O8?%U\UX7EA\7+VF)K9;6:G:,?:RE"<J4G&*24T^1Z)
M*7QVNF?Y!\04<%PQ]+3,.(LJA[#!91XCY/SJ,G+V=#"/+,#FM+VDI2FX2IPQ
MM&2E)M)RBWT7]*]%%%?BQ_L2?SK?\')O[+)^,O[%FC_'70=+-YXO_9F\61:Y
M>S6UNLMX_P -O&\ECX=\70[@/,-MIVL)X4UZX/*VUCIFHW'RH)=W\HG_  1Y
M_:C7]DW]O_X&^/-5U$Z=X)\8:T?A-\1)'?9:CPG\1'@T07U\VY0MGX?\0-H7
MB:9VR(UT7<00"#_I2_%;X;^&OC%\,OB#\*/&-JM[X5^)'@WQ)X(\06S(DA?2
MO$VD7>D7C1K("HGAANVFMG(S%<1QR*0R C_)Z^.?PF\4?L^?&SXG?!KQ4LMO
MXH^%/C[Q)X+U&54:V,UWX:UBYL(]1M@'9DM[^.WBU"RD5SNMKB&1&((-?VG]
M'G-,+Q9P)Q3X=9K/GAAJ>*C1@]9K*,]I5:5;V,7IS8+,%6Q"G=<E7&4;6LF?
M,9S3EA\70QM-6<G%O>WM:+3CS>4H<JM?509_KB5^7/\ P64_:8'[+?\ P3U^
M//B^POC9>+_'>A#X.^!&CD$5S_PD7Q(2?1;N[M6Y9;C1?"Q\1:_$ZJ<2Z7&I
M*[@P] _X):?M0)^UW^PM\!/B[>7BWGBU/"D'@;XB'<3,OCWP%M\-Z_<W ;+)
M+K?V*U\2HA)Q;:W;D,P(8_S5_P#!TC^TN^O_ !3^!/[)^B7X?3OA_P"'KKXN
M>-K2%V*OXI\8O<:'X3M;M0VP7.C^&]-U*_@4@2+;^+0Y^25"?PCPWX%Q68^*
MV7\+9C0O_8><8FMG5-J]/V.0UIU*].>]Z.+Q%&CA(R6DEBH-.S3/6QN+C#+Y
M8B#_ (U.*I:ZWK))?.,6Y/\ PO8P_P#@UV_9G;Q9\;_C7^U5K=AYFE_"CPM;
M_#;P7=RHIC;QK\0,W?B"ZM&(.VYT;PAIK6%SMVL+?QC$,A)&#_VPZ[JL6AZ)
MK&MW&#!H^E:AJLVX[5\K3[2:[DW-SM&R%LGL.:_+?_@BG^S*O[+_ /P3Q^!^
M@ZA8FS\8_$[3)/C7XW\V%(;HZM\18[;4M%L[D#+B72/!D7AC29$=B4N+.X8!
M3(PK]&_BY:W%]\*?B=96F[[7>?#WQI:VNWEOM%QX;U**':/[WF.N/?%<_BUQ
M)'B_Q*SK&1JJ>!P^/IY)@9)WIK!9;-81U:;O_#Q.(6)QJ>G^\-Z#RZA]6P-*
M-K2E!U9Z:\TUS)-=XQY8?]NG^2S\3O&5_P#$7XD>/_B!JEQ)=ZGXX\:>*/%^
MHW4K%I;F^\2:W>ZQ=3R,V27EGO)';/0L1QBOZ)_V=O\ @XT\8?LP?LU_!K]G
M?X<?LI>$M2@^$W@+2?"/_"5>)_B/K4RZW?V:R2ZAK#:!I/A?33:+J-_<7-XU
ML-<N'1IF4W#GYS_-&XVR.&4KAVRI&"N&.5(/0CH0:_TZ/^"=_P &_P!G3Q]^
MPO\ LD>,Y/@?\&=3O]9_9_\ A9)J>K7/PQ\$W5]J.L:?X2TS2]5OKV]FT-[F
M[OIM2LKI[JZN))+F:X,DDTCRL['^O?''-N$^'\BX>_UHX3J<4Y;_ &E.C@L)
M2S3$992PF)HX.2IU)RPW\=2P[K4Z=.:<8I2:6NGSF54\16JU?88A8>I[-2G)
MPC4<HN:YE[VVMFVO(_E0\:_\'.O[?>OM,OA3P)^SWX"@;B)['P9XKU^]B&>"
MT_B'QM?6<C8QR=/1=V3MQA1\D_$+_@O!_P %/?B-IVIZ1??'Z#P_I>L6=YIU
M]9>$OAS\.M&22QOX'M;FU6X_X1>YO422WD>+S!=?: '++,),./\ 1!@^ ?P*
MM<?9?@M\)K;&X#R/ASX/AP'^\!Y>C+C=_%Z]\UMP?"GX76I!M?AMX!MB.A@\
M'>'82,+M&/+TY<87Y>/X>.E?@&$\7_"[+G!X/P4R=R@TXSQ6,P.*J1:LTU4Q
M>38JI=-73YK^>]_7EEN/G\>:5-=U&,XKITC5BK;Z6['^1)';W$K@1PRR$G.$
MC=CZGH#V!/TK_5L_81L;O3/V)?V0["_61+RU_9G^!T5PDJ[9(Y1\-?#9:-UP
M"K1Y"$$ C;@\YKZ(@\%^#K4 6WA/PU;@  "#0M+A  !  \NU7@ D =@2!P:Z
M-$2-$CC18XXU5(XT4(B(@"JB*H"JJJ %4      "OG/%CQBCXFX'*,%#A^62
MQRO%XC%.I+,UF#KNO1A14%%8#!^R4.5R;YJG-=*RY;O?+\M>!G4DZRJ^TC&-
MO9\EK-N]^>5_N1_'O_P==?ZC]B?_ *Z?';_T'X4UX5_P:L_\G(_M/?\ 9$-"
M_P#4\TJO=?\ @ZZ_U'[$_P#UT^.W_H/PIKPK_@U9_P"3D?VGO^R(:%_ZGFE5
M^QY=_P HJ8G_ + <P_\ 6TJGFU/^2@7^.G_ZBQ/[?Z***_BT^G/XN/\ @ZW_
M .2D?L8_]B1\9O\ T_?#ZL?_ (-3_P#DL_[7'_9,/AU_ZE>M5L?\'6__ "4C
M]C'_ +$CXS?^G[X?5C_\&I__ "6?]KC_ +)A\.O_ %*]:K^UJ?\ RBE+_L6U
M/_6V9\P_^2@_[?C_ .HJ/[7Z_P W#_@OO_RE3_:3_P"N'PG_ /5.^ J_TCZ_
MS</^"^__ "E3_:3_ .N'PG_]4[X"K\[^B[_R7^:_]DGC_P#U;9*=F??[I3_Z
M_P ?_2*A_4-_P;2?\HWIO^S@?B;_ .F7P+7]!-?S[?\ !M)_RC>F_P"S@?B;
M_P"F7P+7]!-?F'BS_P G+XV_[*',/_3K.[+?]PPG_7BG_P"DH*^=OVMOV?M!
M_:H_9J^-'[/OB(0+9?%#P'K7AZRN[B-9$TGQ%Y(OO"FNA65LOH7B:STG5TVX
M8M9 *RDY'T317PN#Q>(R_%X7'X2K*CB\%B:&+PM:/Q4L1AJL:U&K'^]3J0C)
M>:1USC&<90DKQG%QDN\9)IKYIM'^03XL\,>)/AQXU\1>#O$=G<:)XM\#>)=5
M\.ZW8.S1W6E:_P"'-3GT[4+4NNUEFL]0LY8MZX(>/<I'%?Z@/_!,?]J!/VO_
M -B#X"_&BZNX[KQ5>^$H/"?Q#"/NDB^('@ECX:\3RSKUA;5[JP3Q#!$22MCK
M%H=S!@Q_C1_X.+OV45^ G[<US\6] TPV?@?]IW01\0H9(8]EE#\0M(>#1?B)
M8Q[5"K<7=U_8_BRZR29;CQ5,X/#*OW-_P:X?M4+I7C#XX?L>^(=2*6OBRQ@^
M,WPWM;B:0Q#7M"CM- \>Z=9(Q,8N=3T)_#NK"&,#=;^&M0N,960M_;OC#AL/
MXD>#V3<<Y=3C+$Y71PV=.$%SSI8;%*&"S[!)J^F#Q485:TF[*.6S?5GRV6RE
M@LRJ86;]V;E2NU9.4??HS_[>BVH[ZU$?V=LRHK.[*B(I9W8A555!+,S$@*J@
M$DD@  DG%?YG7[7'C+Q)_P %,?\ @JWXML?"%Y-J=O\ %[X]:+\'OAO/%BYM
M['P%HFK67@3P_JT$:D(M@F@Z:_BN^VD!FN;^Y<!Y'%?W6?\ !6;]I2/]E;]@
M/]H7XDVU^;#Q3J_A"Y^&O@%XV9;EO&?Q&5_#&FW%H5PPGT6SO=2\29!5EAT6
M9E96 (_E(_X-F_V9S\4OVQ/&?[0NMZ<+KPY^SKX(G;2;JXM_,@'Q&^)*7WA_
M1#$\G[LSV7A>W\97F4#26UQ]@FS&SQ,WYMX'PAPCP=XA>*&)A%3P&7RR7)95
M$N6IC9*C7G37,G>-;'ULFH<T4[)5HN]I)=V:MXC$X+ 1>DYJK52_DNU?U4%5
M>_5']T7P]\#>'_ACX"\%?#?PG:+8>%_ /A3P_P"#?#MFH4"VT7PUI-IHVF0G
M:%4NEG9PB1\ N^YSRQ-=A117\RU*DZM2=6K.52I5G*I4J3;E.<YR<ISE)ZN4
MI-N3>K;;9[B2222LDDDELDM$OD%?S9?\'"/_  307]I#X0O^UQ\(O#_VCXW_
M  /T"4>.=,TNT,FH?$7X1:<9[V[_ '4 \R\U_P"'YEN]9TY@KW%WX>EUK3L7
M$UMH]O'_ $FUYU\7/B?X!^"WPQ\=?%;XI:W9>'?A[X"\-:GXC\6ZOJ"B2WMM
M'L(&:>,6Y!:]NKUBEC8:=$DEQJ5]<VUA;12W%Q'&WT_!7$F<<*<393G61QJ5
M<?0Q5.E'!P4Y+,J6(E&C6RZ=."<JD<9"7L8QC&4XU73JTDJU.G)88JA3Q%"I
M2JM*$HM\[M^[:5U--Z+EWO=*UT]&S_+4_8V_;+^-7["_QD@^-7P0U6TL_$0\
M/Z]X8U71]:@EO?#?B'1]<L)+?['KVF1SVYO8],U-=/U_3AYT;0:OI-C,6:)9
MH9?U1_X(R_\ !/?Q9_P4@_:@\2?M(_M$_P!K>*O@O\/_ !A)XT^)6M^(6N)Y
M/C%\4M3O#KMMX+DO'*_;;::YF&O^.&C9EBT=K72'6%O$-K/#^,_[1OCGP!\3
MOCS\7OB%\*O D7PQ^''C+X@^*/$?@OP%!<&YB\+>'M5U:YN].TM7'[J'RX9%
M<V=M_H6GM(;&Q)L[: G^B+_@W0_X*36_P9^(DO[$7Q<UF&T^&WQ?U]M3^$&N
M:A,(K?PG\5;Z..WN/#$\SX2+2OB%';VEO8F1PEIXKM+**-<>(+R:'_0;Q,CG
M.#X'XBXCX4RJGA.*L;DN#HYCB%&FLXPN4T?:5<93I5L/SJMC<LHXG%.E[.LU
M"U2OAZE6K0PU.?Q^!]E+%4:&(J.6'C5DX1U]G*I*RBVG9J,W&-[K;222<F?W
M(000VT,-M;0Q6]O;Q1P0001I%#!#$@CBAABC"I'%&BJD<:*J(BA5   J6BBO
M\S]]S[@**** /Q\^.'B9=0^(GB^9)-XCUO4K8,#QBTO+BW4#G!"QQ*B\?=49
M).<_->K:P?G^;'![GISSGCWZ?,3WS6KXY\1G4-?UR_) :]U.^NF XPT]Q+*V
M-Q!ZN3Z\_EXQJVK\/\W3/X=><9.?Z=N.O[)AZ?LZ-"FEI3I4H6\HPC'Y)6/\
MTN+.(_K./S#$.HW]8QF*KW<M_;5YS;=^_-^*\R35=7)+ ,23P,9Y)P./?Z?@
M#D8_<S]D+PG+X3^ W@];F,QW?B%+KQ5<!D\MFCUB13ISNN =SZ/!IS9;YL$
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M)U_'ZT^+'@^R'B?P;X@M(?#7Q6^'=Q=O9VGC/PB;M+G%K<@21Z?XDT2<-?\
MAS5G@G6TN3<6EQ%+IVHZA;S?Z 9_@(^.'@WEV(RBK1J9Y0IX/'TJ,IP@HY_E
MM">%S++JLY.*H/$PKXJ.&E5<(-5L'B*CC0ESKX^C/^RLRG&HG[)\T&TKMT9M
M2A-+KRM1<DKO225WH?ZCE%?EI^S]_P %G/\ @G1^T'X9T[6]._:-\%?#+6[J
M%#J'@?XSZI9?#;Q-I%V5'FVDDFO7,.@:MY;$A;OP_K>JVDBX;S58E!ZQXK_X
M*C?\$[/!=O+<:[^V9^S[MA1W:#1/B)HGBJ_98_O^5IOA:?6=0G8=-D%K(Y)
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M+26QO[.XC8%9(+JTGE@E1@5>-V4@@FO\J7]N?]FO5OV1/VLOCC^S[J:3&V\
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MC%U</-J-10<N>*;TG&,EK%'95I1K4YTI.2C-6;A)QE:Z>C6U[6?E='\$-_\
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MIL\VL7BZO"U]/;66O"YBFBN)IK:U67]]_$WAGX:?''P'J/AOQ%9>&?B-\/\
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M0PV%PN&X_P"'*.'PV'H4HQIT:%"C"%*C2IQC"G3C&$(J,4E^U]?B#X,D2/\
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M0]G456IAY8>\T[N#I2G-N*LKN]I)M6TU_I'AK%<4\2\-8M<:\,4^"<VQCQV
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MI06KLM93G+>=2I)RG4G+WISE*3=VPHHHK@.T**** "BBB@ HHHH _G>_:O\
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M4/+E(+6>FZ>'N54QI>6Q<2I^U$D:2H\<J))'(K))'(H='1@59'1@5964D,K
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M_P!Y&C3A5C##./*^:,)5IRIR<UR1?(HVLU\GE/@=DF0^-N;^,V3YA5P57/\
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M!655/$#%\.UH?5L3DM?C'^T5A:U;%8&4\)B,\JY#/,*JJ3J3C*<I7^"/A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>vtyx-20250617.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-06-16T20:10:15.7871+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://ventyxbio.com/20250617" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:vtyx="http://ventyxbio.com/20250617" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="vtyx-20250617.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 17,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VENTYX BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001851194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2996852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12790 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">407-6511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VTYX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="vtyx-20250617.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="vtyx-20250617.htm">vtyx-20250617.htm</File>
    <File>vtyx-20250617.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vtyx-20250617.htm": {
   "nsprefix": "vtyx",
   "nsuri": "http://ventyxbio.com/20250617",
   "dts": {
    "inline": {
     "local": [
      "vtyx-20250617.htm"
     ]
    },
    "schema": {
     "local": [
      "vtyx-20250617.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_ac5e1666-957d-489c-9bd7-cbb1a971398f",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtyx-20250617.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ac5e1666-957d-489c-9bd7-cbb1a971398f",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtyx-20250617.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ventyxbio.com/20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0000950170-25-087068-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-087068-xbrl.zip
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M7.8=2;4=_&BG_.I;+^$SDN6S2+S;F3*.3-]WII=[$Y:>A7&?%7GRUW R35+
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MKEXQ*9XN;2^Z (F7>)E(S]&71'I#PEPF0ZESQ,J:UDOKZC8Z3&,"?;.<@M&
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MY4)+D(#Y\"%\$:B5H%&Y$HMQI,#$XH+%R-AAKE_6*0:_K$_Q0/6(0%D'8 F
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M8HIEG&CN2',O!(-]"LNKN!>MH;BL8972 /QU3"* I(P+M"^+5+(MB@R6HI6
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M60(\@(O+8E*MPYX$0ZVZ,FJXR/PT]!:FXE6TAW+VM=T>V;5^GZIWSQ:F5:W
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M'P5PF$J;W/4<M37GR/(BFE4I_GI)-0SC8>;]+%:Y3,PK>V+,HJ"JPY3&:]D
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M^/[[W148V ]P8H$+8@<3B'V@@0??GY[J^FPV:SLCA#WB!C[+SFO;9*(#38O
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MW\>EK89'Q 0LG-N'MTD2;9)$7S1)U-ADA&E.8U0L:^EL[M&KDQ6KJL;--"M
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M!.4['7L*=H!SL!'/*V#_H?]TU6Q-!5;X?46YPZ6)GYVL5SJ.?</1]N\076.
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M_P-02P$"% ,4    "  -0-%:!6T=+;4=   #YP  $0              @ $
M    =G1Y>"TR,#(U,#8Q-RYH=&U02P$"% ,4    "  -0-%:%;WJAX<(   .
M80  $0              @ 'D'0  =G1Y>"TR,#(U,#8Q-RYX<V102P$"% ,4
M    "  -0-%: +16OL\7  #)E@  #P              @ &:)@  =G1Y>"UE
?>#DY7S$N:'1M4$L%!@     #  , NP   )8^      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>vtyx-20250617_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vtyx-20250617.xsd" xlink:type="simple"/>
    <context id="C_ac5e1666-957d-489c-9bd7-cbb1a971398f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001851194</identifier>
        </entity>
        <period>
            <startDate>2025-06-17</startDate>
            <endDate>2025-06-17</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_17ef4d16-81c4-4b61-8ac4-b458e72e019a">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_1ef6366d-ea1d-44f6-a3f4-b068f20a9b09">0001851194</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_194c83bc-a4a5-4150-a45a-0583ee835261">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_cea4b8c1-5323-43f6-838d-83ba0c408d4d">2025-06-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_e60820d7-78b6-4db8-ac6b-546ff0938ca1">VENTYX BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_c5bc63e4-7739-4cc0-a6af-6d7c667fed73">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_37c43592-87e3-4dd6-9f6d-7f4b071293bd">001-40928</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_96c50338-f833-490a-bf4a-0d6db6676e02">83-2996852</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_83b36abe-9d02-4733-b294-dff60f0e6fe7">12790 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_7ad14e67-c52c-4a6e-b1d0-24b3104f318b">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_649e0921-571a-499c-acc4-cdbaf7f0688b">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_d4a365cc-aba8-4f90-8a40-b87db098a681">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_ce51e629-d4a0-4f67-8388-eb7c37d63a55">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_bd51347b-9974-47bd-8dd4-ecabde4aedde">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_71808cd5-234d-47e0-878a-7a9b27842df7">407-6511</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_14fc0fae-6762-4bde-9186-fb564babafbf">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_5db35dc3-6102-493f-bd88-9c5c9060494c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_ef5ede58-39ad-4fc0-aab1-1869d1469e51">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_495bbfe1-9ace-4cbd-96e4-e97f9df68732">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_5ca31d10-838c-493e-befd-bdfda48383d4">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_9a09f27e-17f4-4eac-a023-f351928ab1ed">VTYX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_f41c9fd4-b972-4d38-a80b-3573ff26f468">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_ac5e1666-957d-489c-9bd7-cbb1a971398f"
      id="F_fd409922-f515-4f3a-a938-2f419cdde066">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
